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LETTERS TO THE EDITOR
Dear Editor,
EXPANDED NEWBORN SCREENING PROGRAMME IN SAUDI
ARABIA: ARE WE READY?
We read with interest the article by Alfadhel et al. on Saudi
newborn screening.1 We would like to highlight the following:
1 The reported incidence was 1:0432; the incidence of the screened
metabolic disorders was 1:1443, which is comparable to other
gulf countries but still underestimated.3,4 The incidence reported
in previous pilot studies in Saudi Arabia for the period
1995–1998 was 1:1381,1 and for the year 2000, the incidence
was 1:690 (personal experience).
2 It is important to implement a good legislative system and edu-
cation for public, medical professionals and legislators, with the
establishment of an integrated infrastructure with policies and
guidelines and financial and legislative support prior to estab-
lishing nationwide newborn screening (NBS).
3 Homocystinuria must be included as it meets NBS committee
selection criteria, with the establishment of a rapid method for
detecting the total homocysteine in dried blood spots by
MS/MS.3 Other common disorders to be included are tyrosine-
mia type 1, very long chain acylcoA dehydrogenase deficiency
and 3 methyl glutaconic aciduria.
4 The time for the second recall sample and time lag from the
first suspicion till implementation of specific therapy is not
stated clearly, which is, in my experience, between 1 week and
a month, which is too long to pre-symptomatically treat cases.
We encounter these cases in our emergency department before
the results. This has ethical and prognostic implications.
5 The false positive results were 0.56%; however, no false negative
results were reported, which is important to assess the efficacy of
the testing system and the measures taken to identify these
cases.
6 Although a good proficient specimen work flow has been put in
place, it is not linked to the clinical management of the patients.
7 Only 51% of the positive cases were retested, which could be
related to poor legislative recall system and the wide geograph-
ical area of Saudi Arabia.
8 It is important to report how many proven positive cases have
been managed and what is the long-term follow-up and
prognosis.
9 It is useful to know what second-tier testing was used to con-
firm positive cases like molecular testing and what further
management and family counselling measures are used for fur-
ther preventive reproductive options.
Finally, we want to stress that NBS as a population-based
screening must function as a system2,3 with the pre-analytic, ana-
lytical and post-analytical phases, with continuous system audit
and improvement.
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Dear Editor,
INFANTILE POMPE DISEASE AND ENZYME REPLACEMENT
THERAPY
We describe an interesting case of infantile Pompe disease and
the effect of enzyme replacement therapy. A 1-week-old female,
born at term, was brought to the emergency room with marked
respiratory distress. A chest X-ray obtained in the emergency
room revealed severe cardiomegaly. An electrocardiogram (ECG)
was performed, which showed short PR interval and biventricu-
lar hypertrophy with strain pattern. Subsequent echocardiogram
revealed severe left ventricular hypertrophy and moderately
depressed left ventricular function. Acid α-glucosidase (GAA)
activity on dried blood spot was found to be reduced, and urine
hexose tetrasaccharide level was found to be markedly elevated,
suggestive of Pompe disease. Molecular analysis of the GAA gene
by sequencing revealed two mutations (c.1210G > A and
c.2227C > T), thus confirming the diagnosis of Pompe disease. A
skin biopsy was performed to determine cross-reacting immuno-
logical material (CRIM) status in order to assess her ability to
respond to enzyme replacement therapy. She was CRIM positive.
Subsequently, she underwent recombinant human GAA replace-
ment at biweekly intervals. After 2.5 years of treatment, there is
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near complete resolution of the abnormalities seen on her initial
ECG and echocardiogram, along with normalisation of left ven-
tricular function (Fig. 1). Pompe disease (glycogen storage disease
type II) is an autosomal recessive disorder caused by deficiency of
the lysosomal enzyme GAA, leading to generalised accumulation
of lysosomal glycogen in the heart, skeletal and smooth muscle
and the nervous system. This disease was first identified in the
1930s by Dr Pompe.1 Infants with infantile (classic) Pompe disease
typically present during the first few months of life with hypoto-
nia, macroglossia, feeding difficulties, respiratory distress and car-
diomegaly. Lysosomal glycogen deposition in heart results in
hypertrophic cardiomyopathy and conduction abnormalities. If
untreated, it results in death mostly from cardiorespiratory failure
by 1 year of life.2,3 Enzyme replacement therapy by recombinant
human GAA decreases left ventricular mass, improves skeletal
muscle function and prolongs overall survival.4 It also improves
left ventricular voltages, QT dispersion and PR intervals on ECG.5
Our case is a visual illustration of near complete resolution of elec-
trocardiographic (short PR interval, biventricular hypertrophy)
and echocardiographic (severe left ventricular hypertrophy,
depressed left ventricular function) abnormalities in a case of
infantile Pompe disease through the use of biweekly recombinant
human GAA replacement.
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Fig. 1 Echocardiogram: Parasternal long axis view (a) pre- and (b) post-enzyme replacement therapy showing complete resolution of left ventricular hyper-
trophy. Electrocardiogram: (c) Pre- and (d) post-enzyme replacement therapy showing improvement in biventricular hypertrophy (decreased voltages).
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